Client: Janssen Australia
Janssen is a global leader in the science and medicine of Pulmonary Arterial Hypertension having launched the first endothelin receptor antagonist (ERA) bostentan, in 2001. Since then Janssen has development a portfolio of PAH treatments including macitentan and a generic epoprostenal with improved thermal stability.
When Janssen wanted to publish clinical case studies on bosentan, Leo Creative named and created PAH Clinic – a corporate (rather than product) branded, journal-like publication to reinforce Janssen’s leadership in PAH. The publication has proved to be one of Janssen’s most useful in-field resources – working across their PAH product portfolio and providing a vehicle for engaging with Key Opinion Leaders.
This regular publication has evolved over time beyond patient case studies to cover speaker tours and updates to global diagnosis and treatment guidelines.